| Literature DB >> 26132075 |
Giuseppe La Regina1, Ruoli Bai2, Antonio Coluccia1, Valeria Famiglini1, Sveva Pelliccia3, Sara Passacantilli1, Carmela Mazzoccoli4, Vitalba Ruggieri4, Annalisa Verrico5, Andrea Miele5, Ludovica Monti1, Marianna Nalli1, Romina Alfonsi6, Lucia Di Marcotullio6,7, Alberto Gulino6, Biancamaria Ricci6, Alessandra Soriani6, Angela Santoni5,6, Michele Caraglia8, Stefania Porto8, Eleonora Da Pozzo9, Claudia Martini9, Andrea Brancale10, Luciana Marinelli3, Ettore Novellino3, Stefania Vultaggio11, Mario Varasi11, Ciro Mercurio12, Chiara Bigogno13, Giulio Dondio13, Ernest Hamel2, Patrizia Lavia5, Romano Silvestri1.
Abstract
We designed 39 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-trimethoxyphenyl moiety with a sulfur, ketone, or methylene bridging group at position 3 of the indole and with halogen or methoxy substituent(s) at positions 4-7. Compounds 33 and 44 strongly inhibited the growth of the P-glycoprotein-overexpressing multi-drug-resistant cell lines NCI/ADR-RES and Messa/Dx5. At 10 nM, 33 and 44 stimulated the cytotoxic activity of NK cells. At 20-50 nM, 33 and 44 arrested >80% of HeLa cells in the G2/M phase of the cell cycle, with stable arrest of mitotic progression. Cell cycle arrest was followed by cell death. Indoles 33, 44, and 81 showed strong inhibition of the SAG-induced Hedgehog signaling activation in NIH3T3 Shh-Light II cells with IC50 values of 19, 72, and 38 nM, respectively. Compounds of this class potently inhibited tubulin polymerization and cancer cell growth, including stimulation of natural killer cell cytotoxic activity and repression of Hedgehog-dependent cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26132075 PMCID: PMC4552448 DOI: 10.1021/acs.jmedchem.5b00310
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446